ArticleNeuro-oncology advances
Stereotactic radiosurgery for brain metastasis from gynecological cancers: A systematic review.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Though rare in gynecologic cancers, brain metastases have become more frequently diagnosed, likely due to improved treatments and clinical awareness. Stereotactic radiosurgery (SRS) is a precise treatment option showing promise for these cases. This systematic literature review evaluates the outcomes of SRS for gynecologic cancer brain metastases to guide clinical decision-making. Methods: This systematic review followed PRISMA guidelines to identify clinical studies on the use of SRS for brain metastases from gynecological cancers. Searches were conducted in PubMed, Scopus, and EMBASE for English-only articles from 2000 to 2024, and studies were independently screened by three authors. Study bias was evaluated across seven domains. Results: Fourteen studies met criteria, encompassing 534 patients. The most common gynecological cancer studied was ovarian (299/534, 56.0%), followed by endometrial (136/534, 25.5%), and cervical cancer (93/534, 17.4%). The mean KPS was 79.0 (range, 20-100). The mean time from primary cancer diagnosis to brain metastasis diagnosis was 44.3 months (range, -1-428 months). Local control rates ranged from 66.7% to 100% with the mean, 1-year local control rate being 87.6%. Overall survival from brain metastasis diagnosis ranged from 5 to 18.5 months; higher KPS, older age, whole brain radiotherapy prior to SRS, fewer metastases, and controlled primary cancer were associated with improved survival. Conclusion: Brain metastases in gynecologic cancers are rising due to improved survival. This review suggests SRS as a promising treatment, offering survival outcomes similar to other cancer types. Further research is needed to enhance prognostication and patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.